Bio-Connect

anti-TcdB (Clostridioides difficile exotoxin), mAb (rec.) (SH1429-B1)

Research Use Only
AG-27B-6334
AdipoGen Life Sciences
ApplicationsFunctional Assay, Western Blot, ELISA
Product group Antibodies
ReactivityBacteria
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    anti-TcdB (Clostridioides difficile extoxin), mAb (rec.) (SH1429-B1)
  • Delivery Days Customer
    10
  • Antibody Specificity
    Recognizes TcdB from Clostridioides difficile.
  • Applications
    Functional Assay, Western Blot, ELISA
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    SH1429-B1
  • Concentration
    1 mg/ml
  • Estimated Purity
    >95%
  • Host
    Human
  • Isotype
    IgG1
  • Scientific Description
    Clostridioides difficile is a spore-forming, anaerobic, and gram-positive bacterium, that opportunistically colonizes human colon and induces diseases such as diarrhea and pseudomembranous colitis. The symptoms of C. difficile infection (CDI) are mainly caused by two primary exotoxins, TcdA and TcdB, released from the bacterium. Both TcdA and TcdB belong to the family of large clostridial toxins (LCTs), which contain an N-terminal glucosyltransferase domain that modifies small GTPase proteins, a cysteine protease domain (CPD) that autocatalytically cleave the holotoxin in the cytosol, a combined domain for both delivery and receptor binding, and a C-terminal region consisting of series of combined repetitive oligopeptides (CROPs). These toxins enter host cells via receptor-mediated endocytosis and inactivate small GTPase proteins, leading to actin cytoskeleton disruption and cell death. Of the two toxins, TcdB alone is able to induce a full spectrum of diseases in both animals and humans. Although different toxin receptors have been identified, it is no valid therapeutic option to prevent receptor endocytosis. Neutralizing antibodies, directly targeting both toxins are so far the only therapeutic approaches. - Recombinant Antibody. Recognizes TcdB from Clostridioides difficile. Applications: ELISA, FUNC, WB. Clone: SH1429-B1. Isotype: Human IgG1. Formulation: Liquid. In PBS. Clostridioides difficile is a spore-forming, anaerobic, and gram-positive bacterium, that opportunistically colonizes human colon and induces diseases such as diarrhea and pseudomembranous colitis. The symptoms of C. difficile infection (CDI) are mainly caused by two primary exotoxins, TcdA and TcdB, released from the bacterium. Both TcdA and TcdB belong to the family of large clostridial toxins (LCTs), which contain an N-terminal glucosyltransferase domain that modifies small GTPase proteins, a cysteine protease domain (CPD) that autocatalytically cleave the holotoxin in the cytosol, a combined domain for both delivery and receptor binding, and a C-terminal region consisting of series of combined repetitive oligopeptides (CROPs). These toxins enter host cells via receptor-mediated endocytosis and inactivate small GTPase proteins, leading to actin cytoskeleton disruption and cell death. Of the two toxins, TcdB alone is able to induce a full spectrum of diseases in both animals and humans. Although different toxin receptors have been identified, it is no valid therapeutic option to prevent receptor endocytosis. Neutralizing antibodies, directly targeting both toxins are so far the only therapeutic approaches.
  • Reactivity
    Bacteria
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352203